Literature DB >> 26034218

New strategies in melanoma: entering the era of combinatorial therapy.

Ryan J Sullivan1, Keith T Flaherty2.   

Abstract

The treatment of metastatic melanoma has been revolutionized over the past decade as effective molecularly targeted therapies and immunotherapies entered the clinic. It is hoped that deeper insights into the characteristics of patients and tumors that are most responsive will allow more precise patient selection for these therapies while understanding mechanisms of resistance will facilitate the develop of rational combinations or next-generation agents aimed at novel targets. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26034218     DOI: 10.1158/1078-0432.CCR-14-1650

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.

Authors:  Yi-qun Guo; Ya Ding; Dan-dan Li; Jing-jing Li; Rui-qing Peng; Xi-zhi Wen; Xing Zhang; Xiao-Shi Zhang
Journal:  Med Oncol       Date:  2015-08-23       Impact factor: 3.064

2.  Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood.

Authors:  Michael S Gee; Arezou A Ghazani; Rizwan Haq; Jennifer A Wargo; Matthew Sebas; Ryan J Sullivan; Hakho Lee; Ralph Weissleder
Journal:  Nanomedicine       Date:  2016-12-18       Impact factor: 5.307

Review 3.  The discovery and development of binimetinib for the treatment of melanoma.

Authors:  Brian Tran; Mark S Cohen
Journal:  Expert Opin Drug Discov       Date:  2020-04-04       Impact factor: 6.098

4.  RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.

Authors:  Manfred Kunz; Henry Löffler-Wirth; Michael Dannemann; Edith Willscher; Gero Doose; Janet Kelso; Tina Kottek; Birgit Nickel; Lydia Hopp; Jenny Landsberg; Steve Hoffmann; Thomas Tüting; Paola Zigrino; Cornelia Mauch; Jochen Utikal; Mirjana Ziemer; Hans-Joachim Schulze; Michael Hölzel; Alexander Roesch; Susanne Kneitz; Svenja Meierjohann; Anja Bosserhoff; Hans Binder; Manfred Schartl
Journal:  Oncogene       Date:  2018-07-11       Impact factor: 9.867

Review 5.  Focus on cutaneous and uveal melanoma specificities.

Authors:  Charlotte Pandiani; Guillaume E Béranger; Justine Leclerc; Robert Ballotti; Corine Bertolotto
Journal:  Genes Dev       Date:  2017-04-15       Impact factor: 11.361

6.  Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib.

Authors:  Marcin Rajczykowski; Grazyna Kaminska-Winciorek; Elzbieta Nowara; Marzenna Samborska-Plewicka; Sebastian Giebel
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

7.  Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis.

Authors:  Terje Sundstrøm; Lars Prestegarden; Francisco Azuaje; Synnøve Nymark Aasen; Gro Vatne Røsland; Jobin K Varughese; Marzieh Bahador; Simon Bernatz; Yannick Braun; Patrick N Harter; Kai Ove Skaftnesmo; Elizabeth S Ingham; Lisa M Mahakian; Sarah Tam; Clifford G Tepper; Kjell Petersen; Katherine W Ferrara; Karl Johan Tronstad; Morten Lund-Johansen; Rudi Beschorner; Rolf Bjerkvig; Frits Thorsen
Journal:  Acta Neuropathol Commun       Date:  2019-04-10       Impact factor: 7.801

8.  Triphenylphosphonium derivatives disrupt metabolism and inhibit melanoma growth in vivo when delivered via a thermosensitive hydrogel.

Authors:  Kyle C Kloepping; Alora S Kraus; Devin K Hedlund; Colette M Gnade; Brett A Wagner; Michael L McCormick; Melissa A Fath; Dongrim Seol; Tae-Hong Lim; Garry R Buettner; Prabhat C Goswami; F Christopher Pigge; Douglas R Spitz; Michael K Schultz
Journal:  PLoS One       Date:  2020-12-30       Impact factor: 3.240

Review 9.  JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.

Authors:  Garima Pandey; Andrew T Kuykendall; Gary W Reuther
Journal:  Blood Cancer J       Date:  2022-01-26       Impact factor: 11.037

10.  Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.

Authors:  Stefan Kaluz; Qing Zhang; Yuki Kuranaga; Hua Yang; Satoru Osuka; Debanjan Bhattacharya; Narra S Devi; Jiyoung Mun; Wei Wang; Ruiwen Zhang; Mark M Goodman; Hans E Grossniklaus; Erwin G Van Meir
Journal:  Oncogene       Date:  2021-07-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.